For instance, EVs’ release results in increased tumor invasiveness by transferring tumor promoters such as mutant KRAS, Epidermal Growth Factor Receptor (EGFR) and integrins to tumor cells with wild-type KRAS [108]. Here, KRAS is linked to neoplasm.